Bayer drug delays MS in half of patients: MRI study
CHICAGO (Reuters) - A long-term study of brain scans in multiple sclerosis patients showed only about half of the patients who took the drug interferon beta 1-b got a long-lasting benefit, U.S. researchers said on Monday.</p><div class="feedflare">
<img src="http://feedproxy.google.com/~f/reuters/healthNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=YF7BpOir) <img src="http://feedproxy.google.com/~f/reuters/healthNews?i=mSWnZITj" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=mSWnZITj) <img src="http://feedproxy.google.com/~f/reuters/healthNews?i=KR9b6Qgy" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=KR9b6Qgy)
</div><img src="http://feedproxy.google.com/~r/reuters/healthNews/~4/DnW6lKuR0uo" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/DnW6lKuR0uo/idUSTRE4A983R20081110